Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-20-022337
Filing Date
2020-08-14
Accepted
2020-08-14 17:17:05
Documents
1
Period of Report
2020-08-12

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 4192
  Complete submission text file 0001213900-20-022337.txt   5617
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 140 RIVERSIDE DRIVE APT. 9K NEW YORK NY 10024
Business Address
Berger Mark Stanley (Reporting) CIK: 0001700283 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36374 | Film No.: 201106597